Print pageEmail pageRSS Feeds

We are building a strong, well-run business, structured to deliver sustainable results over the long term.

Along with biotechnology leadership, the ARIAD team is focused on its commitment to deliver long-term value to investors through solid business execution. That means maintaining disciplined cost control, thoughtful capital deployment and the highest standards of corporate governance.

Webcast ImageWebcast - Replay
Q1 2015 ARIAD Pharmaceuticals, Inc. Earnings Conference Call
05/07/15 at 8:30 a.m. ET
Q1 2015 ARIAD Pharmaceuticals, Inc. Earnings Conference Call
Thursday, May 7, 2015 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Recent Press Releases
More >>
ARIAD Announces Data Presentations at the European Hematology Association (EHA) Congress
ARIAD to Present at the Jefferies 2015 Global Healthcare Conference
Investor Downloads

Download Documentation Brigatinib Update at ELCC: Analysis of Safety and Efficacy at Selected Phase 2 Doses
Download Documentation Brigatinib Update at ELCC: Evaluation of Brigatinib in Patients with ALK+ NSCLC and Brain Metastases
Download Documentation Investor Presentation
More >>

ARIAD Stock Price: $9.07

Stock Symbol: ARIA

Stock Exchange: NASDAQ

Stock Quote at: 05/22/15

4:00 p.m. ET
(US Dollar)
CHANGE (%) Stock is Up 0.23 (2.60%)
DAY LOW$8.82
52 WK. HIGH$9.89
Minimum 20 minute delay
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
You are now leaving this website. If you would like to continue, click Continue.